Clinical Trials on H7N9 Influenza in Poland

Total 177 results

GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

Influenza

Poland
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
Medical University of Warsaw

Unknown

Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of Medical University of Warsaw

Vaccnation in HCW

Poland
Wroclaw Medical University

Unknown

Incidence of Influenza Infections and Determination of Vaccination Coverage Rate Among Healthcare Workers

Influenza | Vaccination | Attitude of Health Personnel

Poland
Centre of Postgraduate Medical Education

Unknown

Different Regimens in Influenza Postexposure Chemoprophylaxis in Children

Influenza | Prevention | Exposure

Poland
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
BiondVax Pharmaceuticals ltd.

Completed

A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

Influenza

Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
Institute of Cardiology, Warsaw, Poland
Solvay Pharmaceuticals

Completed

Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study

Coronary Artery Disease

Poland
LumiraDx UK Limited

Suspended

Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites (PURSUE)

COVID-19 | SARS-CoV-2 | Influenza A | Influenza B

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. (FluMist)

Influenza

Belgium, Poland, United Kingdom
Wroclaw Medical University

Recruiting

Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis. (VACCINE-CHF)

Heart Failure | Influenza | RSV Infection | Vaccines

Poland
Medical University of Gdansk

Completed

Nebulized Bronchodilators and Cardiac Repolarization

Influence of Nebulized Bronchodilatators on Selected | Electrophysiological Parameters

Poland
FluGen Inc
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza Vaccine

United States
Medical University of Warsaw

Active, not recruiting

Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza

Obesity | Vaccine Adverse Reaction | Vaccine Reaction | Influenza | Tolerance | Pregnancy; Infection | Elderly Infection

Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

Prophylaxis: Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

Influenza

Poland
GlaxoSmithKline

Completed

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Poland, United Kingdom
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Seasonal Influenza

United States
IQuum, Inc.
Roche Molecular Systems, Inc

Completed

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

Influenza A | Respiratory Syncytial Virus (RSV) | Influenza B

United States
Leiden University Medical Center
Erasmus Medical Center

Completed

Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza (RICH-3)

HIV

Netherlands
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Centers for Disease Control and Prevention
Kaiser Permanente; Baylor Scott and White Health; Abt Associates

Completed

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC

Completed

D2560C00015 FluMist Annual Safety Study 2018

Healthy | Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Influenza

United States
Insight Therapeutics, LLC
Brown University

Completed

High Dose Influenza Vaccine in Nursing Home - Pilot Study

Influenza

United States
Hoffmann-La Roche

Completed

Influenza Resistance Information Study (IRIS)

Influenza

Australia, Hong Kong, United States, France, Germany, Netherlands, Norway, Poland
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Influenza

Belgium, Poland, France, Germany, Italy, Spain
MedImmune LLC
AstraZeneca

Completed

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

United States
GlaxoSmithKline

Recruiting

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

Arthralgia | Influenza, Human

Spain, United Kingdom, Poland, Netherlands
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Healthy | Influenza

United States
Insight Therapeutics, LLC
Brown University; Case Western Reserve University

Unknown

High-Dose Influenza Vaccine in Nursing Homes

Influenza

United States
MedImmune LLC

Completed

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine (MI-MA182)

Influenza

United States
Bassett Healthcare
Genentech, Inc.; Viroclinics Biosciences B.V.

Recruiting

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) (COMBO 1)

Influenza

United States
Novartis Vaccines
Novartis Vaccines and Diagnostics S.r.l.

Completed

Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly

Influenza

Poland
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC

Completed

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine (MI-MA205)

Healthy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
MedImmune LLC
AstraZeneca

Suspended

A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age (ICICLE)

Influenza Vaccine Effectiveness

United States, United Kingdom
American Pharmacists Association Foundation

Completed

Project IMPACT Immunizations (IMProving America's Communities Together)

Influenza

United States

3

Subscribe